Skip to main
FTH

FTH Stock Forecast & Price Target

FTH Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Faeth Therapeutics is well-positioned in the biotechnology market with its innovative multi-node inhibition approach for cancer treatment. The company's PIKTOR program, expected to have a higher success rate for endometrial and breast cancer, has a large market opportunity and promising results. However, FTH also faces risks such as potential competition and clinical/regulatory concerns. Thus, it is important to closely monitor the progress of PIKTOR and the company's overall pipeline as well as developments in the broader biotechnology industry.

Bears say

Faeth Therapeutics is facing a number of challenges that may negatively impact their success in developing and commercializing their combination treatment for HR+ metastatic breast cancer and endometrial cancer. These challenges include a lengthy 3-year treatment duration, competition from a new class of treatment, and potential side effects and dosage modifications with their drug PIKTOR. Additionally, their acquisition of KAT6 and development of targeted treatments for PI3K mutant and wild-type tumors may also be risky and costly ventures.

FTH has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sensei Biotherapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sensei Biotherapeutics Inc (FTH) Forecast

Analysts have given FTH a Strong Buy based on their latest research and market trends.

According to 10 analysts, FTH has a Strong Buy consensus rating as of Sep 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sensei Biotherapeutics Inc (FTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.